Detection of lung cancer in silicosis patients using a tumor-marker panel

Schneider, Joachim

doi:10.3233/cbm-2009-0125

Cited by 7 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that the precursor form of surfactant protein B (Pro-SFTPB) is predictive of lung cancer risk . Other markers that have been shown to be useful for the workup and diagnosis of lung cancer include cancer antigen 125 (CA125), cytokeratin-19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA), and human epididymis protein 4 (HE4) . However, there are limited data regarding the performance of these markers in discriminating between future lung cancer cases and controls.…”

Section: Introductionmentioning

confidence: 99%

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It is now generally accepted that multiple protein markers are superior in early diagnosis of NSCLC. For example, CYFRA21-1, as the best single marker was able to only detect 23.3% of NSCLC at stage I [50]. Our findings of preferential localization of MUC1 in exosomes suggest that exosomal MUC1 may be valuable for the panel of protein biomarkers for NSCLC.…”

Section: Discussionmentioning

confidence: 88%

Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells

Pan

Chen

Feng

et al. 2019

IJMS

View full text Add to dashboard Cite

Lung cancer remains to be the leading cause of cancer-related mortality worldwide. Finding new noninvasive biomarkers for lung cancer is still a significant clinical challenge. Exosomes are membrane-bound, nano-sized vesicles that are released by various living cells. Studies on exosomal proteomics may provide clues for developing clinical assays. In this study, we performed semi-quantitative proteomic analysis of proteins that were purified from exosomes of NCI-H838 non-small cell lung cancer cell line, with total cellular membrane proteins as control. In the exosomes, LC-MS/MS by data-independent analysis mode identified 3235 proteins. THBS1, ANXA6, HIST1H4A, COL18A1, MDK, SRGN, ENO1, TUBA4A, SLC3A2, GPI, MIF, MUC1, TALDO1, SLC7A5, ICAM1, HSP90AA1, G6PD, and LRP1 were found to be expressed in exosomes at more than 5-fold higher level as compared to total cellular membrane proteins. A well-known cancer biomarker, MUC1, is expressed at 8.98-fold higher in exosomes than total cellular membrane proteins. Subsequent analysis of plasma exosomes from non-small cell lung cancer (NSCLC) patients by a commercial electrochemiluminescence immunoassay showed that exosomal MUC1 level is 1.5-fold higher than healthy individuals (mean value 1.55 ± 0.16 versus mean value 1.05 ± 0.06, p = 0.0213). In contrast, no significant difference of MUC1 level was found between NSCLC patients and healthy individuals′ plasma (mean value 5.48 ± 0.65 versus mean value 4.16 ± 0.49). These results suggest that certain proteins, such as MUC1, are selectively enriched in the exosome compartment. The mechanisms for their preferential localization and their biological roles remain to be studied.

show abstract

“…Tumour markers CEA, NSE, and CYFRA 21-1 are widely used for lung cancer screening and diagnosis [ 9 - 11 , 15 ]. This case demonstrated the combination of three clinical conditions diagnosed in one patient, including complicated silicosis associated with sarcoidosis and an elevated blood concentration of the NSE biomarker.…”

Section: Discussionmentioning

confidence: 99%

Elevated Levels of the Cancer Marker Neuron-Specific Enolase in a Patient With Coexisting Silicosis and Sarcoidosis

Davaajav,

Dagva,

Dashtseren

et al. 2024

Cureus

View full text Add to dashboard Cite

In a periodical medical checkup, a 39-year-old Mongolian underground miner was diagnosed with silicosis based on chest radiography, computed tomography (CT), and work history. Chest radiography showed diffuse bilateral rounded centrilobular nodules in both lung fields, with upper lobe dominance and large opacities in the right upper zone. Chest CT presented conglomerated massive changes in the right upper lobe and the coalescence of small nodules in the left upper lung. In the blood test, serum levels of the lung cancer marker neuron-specific enolase (NSE) were elevated (24.58 ng/mL). Carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) levels were within the reference range. Subsequent to the suspicion of a tumour in the right upper lobe, a right upper lobectomy was performed. The histopathological examination of the lung specimen revealed the coalescence of numerous silica nodules, accompanied by indications of associated sarcoidosis. The histological features suggested the presence of two concurrent pathological processes: silicosis and sarcoidosis. This case demonstrated the combination of three clinical conditions diagnosed in one patient, including complicated silicosis associated with sarcoidosis and elevated serum NSE levels. This case report may serve as a foundation for future investigations exploring the potential of NSE as a marker for silicosis.

show abstract

Detection of lung cancer in silicosis patients using a tumor-marker panel

Abstract: With the fuzzy classifier and a marker panel a reliable diagnostic tool for the detection of lung cancers in a high risk population is available.

Cited by 7 publications

References 33 publications

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins

Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells

Elevated Levels of the Cancer Marker Neuron-Specific Enolase in a Patient With Coexisting Silicosis and Sarcoidosis

Contact Info

Product

Resources

About